ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO1058

Presence of Bisphenol S in Haemodialysis Patients: Environmental and Dialysis-Associated Exposure

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Ruiz, Alberto, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
  • Mas, Sebastian, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
  • Abaigar, Pedro, Hospital Universitario de Burgos, Burgos, Spain
  • Santos, Javier, Hospital Universitario de Burgos, Burgos, Spain
  • Camarero, Vanesa, Hospital Universitario de Burgos, Burgos, Spain
  • Gonzalez-parra, Emilio E., Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
Background

In recent years, many studies demonstrated the effects xenobiotic of BPA, as results of these evidences; the industries are replacing BPA for different analogues such as Bisphenol S, it is a structural analogue, where in central quaternary carbon has been replaced by a sulfone. Due to of this similitude structural between BPA and BPS further studies promote to investigate the bioavailability and toxicities of BPS, and especially in the renal patient because of neither there is no literature about this group. In this study, our objective is to determine the plasmatic levels of BPS in comparison with BPA in the terminal renal patient and the influence of dialysis membrane.

Methods

The concentration of total BPS, BPA and hippuric acid (free, conjugated with sulphate or glucuronate, or bound to proteins) was determined by single reaction monitoring mass spectrometry (SRM-MS).

Results

BPA and BPS were measured in two groups: one of 10 healthy subjects (blood donors) and the other of 14 patients in hemodialysis (hemodiafiltration) which they were previously dialyzed for a week with cellulose triacetate (CTA) membranes. BPS in healthy controls were in almost all cases below LOD of 0.05 ng/mL, while in hemodialysis patients regardless of the membrane used was 0.32 ± 0.52 ng/mL. BPA in healthy controls range from 0.8 ± 0.7 ng/mL and 16.96 ± 58.57 ng/mL in renal patients. When membranes are compared, we found an increase of both after one dialysis session with polynephron (BPA: 45.63 ± 54.58 ng/mL at pre-dialysis vs 49.41±44.67 ng/mL at post-dialysis; BPS: 0.42±0.35 ng/mL at pre-dialysis vs 0.56 ± 0.36 at post-dialysis). On the other hand, with the polysulphone membrane exist there is a greater increase in the accumulation of BPA compared with BPS (BPA 51.4 ± 60.31 ng/ml at pre-dialysis vs 62.86 ± 77.39 ng/mL at post-dialysis; BPS: 0.59 ± 0.82 ng/mL at pre-dialysis vs 0.58 ± 0.47 at post-dialysis).

Conclusion

Similar to BPA, BPS accumulates in the renal patient as a result of the excretion problems of these patients along with the contribution of the dialysis membranes itself. However, the quantities measured are an order of magnitude lower than those measured for BPA both in a single dialysis session as well as in long-term dialysis (3 months or more).

Funding

  • Government Support - Non-U.S.